In silico design of novel probes for the atypical opioid receptor MRGPRX2

The primate-exclusive MRGPRX2 G protein-coupled receptor (GPCR) has been suggested to modulate pain and itch. Despite putative peptide and small molecule MRGPRX2 agonists, selective nanomolar potency probes have not yet been reported. To identify a MRGPRX2 probe, we first screened 5,695 small molecules and found many opioid compounds activated MRGPRX2, including (−)- and (+)-morphine, hydrocodone, sinomenine, dextromethorphan and the prodynorphin-derived peptides, dynorphin A, dynorphin B, and α- and β-neoendorphin. We used these to select for mutagenesis-validated homology models and docked almost 4 million small molecules. From this docking, we predicted ZINC-3573, which represents a potent MRGPRX2-selective agonist, showing little activity against 315 other GPCRs and 97 representative kinases, and an essentially inactive enantiomer. ZINC-3573 activates endogenous MRGPRX2 in a human mast cell line inducing degranulation and calcium release. MRGPRX2 is a unique atypical opioid-like receptor important for modulating mast cell degranulation, which can now be specifically modulated with ZINC-3573.

[1]  H Yamasaki,et al.  Pharmacology of sinomenine, an anti-rheumatic alkaloid from Sinomenium acutum. , 1976, Acta medica Okayama.

[2]  B. Roth,et al.  Identification of Novel Functionally Selective κ-Opioid Receptor Scaffolds , 2014, Molecular Pharmacology.

[3]  Brian K. Shoichet,et al.  Rapid Context-Dependent Ligand Desolvation in Molecular Docking , 2010, J. Chem. Inf. Model..

[4]  Donald G. Truhlar,et al.  New Class IV Charge Model for Extracting Accurate Partial Charges from Wave Functions , 1998 .

[5]  B. Baldo,et al.  Histamine-Releasing and Allergenic Properties of Opioid Analgesic Drugs: Resolving the Two , 2012, Anaesthesia and intensive care.

[6]  J. Neumeyer,et al.  Preliminary pharmacological evaluation of enantiomeric morphinans. , 2014, ACS chemical neuroscience.

[7]  M. Furuno,et al.  Immunoglobulin E-independent activation of mast cell is mediated by Mrg receptors. , 2006, Biochemical and biophysical research communications.

[8]  Ruben Abagyan,et al.  Identifying ligands at orphan GPCRs: current status using structure‐based approaches , 2016, British journal of pharmacology.

[9]  I. Kuntz,et al.  Automated docking with grid‐based energy evaluation , 1992 .

[10]  Ben M. Webb,et al.  Comparative Protein Structure Modeling Using MODELLER , 2016, Current protocols in bioinformatics.

[11]  Matthew J. O’Meara,et al.  The Recognition of Identical Ligands by Unrelated Proteins. , 2015, ACS chemical biology.

[12]  M. Beato,et al.  Determining the Neurotransmitter Concentration Profile at Active Synapses , 2009, Molecular Neurobiology.

[13]  Qingyi Yang,et al.  Building alternate protein structures using the elastic network model , 2009, Proteins.

[14]  Kamal Kumar,et al.  Neuraxial opioid-induced pruritus: An update , 2013, Journal of anaesthesiology, clinical pharmacology.

[15]  C. Williamson,et al.  Therapeutic perspective. , 1951, California medicine.

[16]  K. Johnson.  An Update. , 1984, Journal of food protection.

[17]  T. Yaksh,et al.  The Emerging Role of Spinal Dynorphin in Chronic Pain: A Therapeutic Perspective. , 2016, Annual review of pharmacology and toxicology.

[18]  E. Lees,et al.  Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases. , 2010, ACS medicinal chemistry letters.

[19]  S. Rees,et al.  Screening β-Arrestin Recruitment for the Identification of Natural Ligands for Orphan G-Protein–Coupled Receptors , 2013, Journal of biomolecular screening.

[20]  J. Kamei,et al.  The pharmacological profile of δ opioid receptor ligands, (+) and (−) TAN-67 on pain modulation , 2001 .

[21]  Michael M. Mysinger,et al.  Structure-based ligand discovery for the protein–protein interface of chemokine receptor CXCR4 , 2012, Proceedings of the National Academy of Sciences.

[22]  H. Schiöth,et al.  The Repertoire of G-Protein–Coupled Receptors in Fully Sequenced Genomes , 2005, Molecular Pharmacology.

[23]  D. Metcalfe,et al.  Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. , 2003, Leukemia research.

[24]  E. Currier,et al.  Discovery of non-peptidergic MrgX1 and MrgX2 receptor agonists and exploration of an initial SAR using solid-phase synthesis. , 2009, Bioorganic & medicinal chemistry letters.

[25]  M. Fidock,et al.  MrgX2 Is a High Potency Cortistatin Receptor Expressed in Dorsal Root Ganglion* , 2003, Journal of Biological Chemistry.

[26]  Maria F. Sassano,et al.  PRESTO-TANGO: an open-source resource for interrogation of the druggable human GPCR-ome , 2015, Nature Structural &Molecular Biology.

[27]  D. Banville,et al.  Proenkephalin A gene products activate a new family of sensory neuron–specific GPCRs , 2002, Nature Neuroscience.

[28]  R. Stead,et al.  Mast cell/nerve interactions in vitro and in vivo. , 1991, The American review of respiratory disease.

[29]  David J. Anderson,et al.  Atypical expansion in mice of the sensory neuron-specific Mrg G protein-coupled receptor family , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  K. Wüthrich,et al.  NMR structure and dynamics of the agonist dynorphin peptide bound to the human kappa opioid receptor , 2015, Proceedings of the National Academy of Sciences.

[31]  M. Rask-Andersen,et al.  The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. , 2014, Annual review of pharmacology and toxicology.

[32]  D. Siegel,et al.  Complanadine A, a selective agonist for the Mas-related G protein-coupled receptor X2. , 2014, Bioorganic & medicinal chemistry letters.

[33]  Bryan L Roth,et al.  Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. , 2011, Annual review of pharmacology and toxicology.

[34]  Gert Vriend,et al.  GPCRDB information system for G protein-coupled receptors , 2003, Nucleic Acids Res..

[35]  C. Shelburne,et al.  A Mast Cell Degranulation Screening Assay for the Identification of Novel Mast Cell Activating Agents. , 2013, MedChemComm.

[36]  Xinzhong Dong,et al.  Identification of a mast cell specific receptor crucial for pseudo-allergic drug reactions , 2014, Nature.

[37]  N. Grishin,et al.  PROMALS3D: a tool for multiple protein sequence and structure alignments , 2008, Nucleic acids research.

[38]  S. Takeda,et al.  Morphine is an exogenous ligand for MrgX2, a G protein-coupled receptor for cortistatin , 2009 .

[39]  Donald G. Truhlar,et al.  MODEL FOR AQUEOUS SOLVATION BASED ON CLASS IV ATOMIC CHARGES AND FIRST SOLVATION SHELL EFFECTS , 1996 .

[40]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[41]  B. Przewłocka,et al.  Minocycline prevents dynorphin-induced neurotoxicity during neuropathic pain in rats , 2014, Neuropharmacology.

[42]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[43]  J. Barker,et al.  Localization of immunoreactive dynorphin in neurons cultured from spinal cord and dorsal root ganglia. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[44]  H. Subramanian,et al.  β-Defensins Activate Human Mast Cells via Mas-Related Gene X2 , 2013, The Journal of Immunology.

[45]  L. Tseng,et al.  dextro-Morphine attenuates the morphine-produced conditioned place preference via the sigma(1) receptor activation in the rat. , 2007, European journal of pharmacology.

[46]  Avner Schlessinger,et al.  Ligand Discovery from a Dopamine D3 Receptor Homology Model and Crystal Structure , 2011, Nature chemical biology.

[47]  Maria F. Sassano,et al.  A Pharmacological Organization of G Protein-coupled Receptors , 2012, Nature Methods.

[48]  Xin Chen,et al.  Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65 , 2015, Nature.

[49]  M. Jacobson.  Epilepsy in aging populations , 2002, Current treatment options in neurology.

[50]  Z. Xiang,et al.  On the role of the crystal environment in determining protein side-chain conformations. , 2002, Journal of molecular biology.

[51]  Yingxiao Li,et al.  Activation of opioid μ-receptor by sinomenine in cell and mice , 2008, Neuroscience Letters.

[52]  David E. Gloriam,et al.  Computer-Aided Discovery of Aromatic l-α-Amino Acids as Agonists of the Orphan G Protein-Coupled Receptor GPR139 , 2014, J. Chem. Inf. Model..

[53]  J. Sein Anand,et al.  [Recreational usage of dextromethorphan--analysis based on internet users experiences]. , 2013, Przeglad lekarski.

[54]  J. Moss,et al.  Histamine Release during Morphine and Fentanyl Anesthesia , 1982, Anesthesiology.

[55]  David J. Anderson,et al.  A Diverse Family of GPCRs Expressed in Specific Subsets of Nociceptive Sensory Neurons , 2001, Cell.

[56]  Andrea Bortolato,et al.  New insights from structural biology into the druggability of G protein-coupled receptors. , 2012, Trends in pharmacological sciences.

[57]  H. Hiyama,et al.  Identification of MrgX2 as a human G-protein-coupled receptor for proadrenomedullin N-terminal peptides. , 2005, Biochemical and biophysical research communications.

[58]  F. Wurm,et al.  Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. , 1996, Nucleic acids research.

[59]  K. Rice,et al.  Stereospecific and nonstereospecific effects of (+)- and (-)-morphine: evidence for a new class of receptors? , 1977, Science.

[60]  Kim A. Sharp,et al.  Polyelectrolyte electrostatics: Salt dependence, entropic, and enthalpic contributions to free energy in the nonlinear Poisson–Boltzmann model , 1995 .

[61]  S. Maier,et al.  Exploring the Neuroimmunopharmacology of Opioids: An Integrative Review of Mechanisms of Central Immune Signaling and Their Implications for Opioid Analgesia , 2011, Pharmacological Reviews.

[62]  J. Irwin,et al.  Docking Screens for Novel Ligands Conferring New Biology. , 2016, Journal of medicinal chemistry.

[63]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .